// App-Quantinova.ai

318 : A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk

Researchers

Presenter

  • Kenneth Saag

Principal Investigators

  • Jeffrey Petersen

  • Maria Luisa Brandi

  • Andrew Karaplis

  • Mattias Lorentzon

  • Thierry Thomas

  • Judy Maddox

  • Michelle Fan

  • Paul D. Meisner

  • Andreas Grauer

Medical Centers

  • University of Alabama, Birmingham, AL

  • Amgen Inc, Thousand Oaks, CA

  • University of Florence, Florence, Italy

  • Montreal University, Montreal, QC, Canada

  • University of Gothenburg and Sahlgrenska University Hospital, Mölndal, Sweden

  • CHU Saint-Etienne, Saint Etienne, France

  • UCB Pharma, Brussels, Belgium

Locations

  • United States

  • Italy

  • Canada

  • Sweden

  • France

  • Belgium

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • Bone Mineral Density

Drug/Treatment

  • Alendronate sodium

  • Romosozumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved